Effect of antifungal drugs against mucormycosis and impact on human health

Abstract

Mucormycosis, a fungal infection caused by fungi Rhizopus oryzae belongs to family Mucorales. These fungi are commonly found in the environment and can be transmitted through inhalation, ingestion, or contact with spores. Healthcare-associated transmission can occur through the use of contaminated medical equipment, such as gauges, spatulas, linens, or faulty air filters that have not been properly disinfected. Certain individuals are at a higher risk of developing mucormycosis, including those with uncontrolled diabetes mellitus in ketoacidosis, cancer patients, organ transplant recipients, and individuals with weakened immune systems lacking phagocytes. These risk factors make them more vulnerable to the infection.The present study aims to provide an overview of various antifungal drugs used against mucormycosis. It also explores the clinical manifestations of mucormycosis and its impact on human health, with a focus on case studies conducted in different countries after the COVID-19 pandemic. These case studies examine the types of mucormycosis cases, the methods of diagnosis, and the systemic effects of the disease. Overall, this study sheds light on the treatment options available for mucormycosis, the diverse clinical presentations of the infection, and its implications for human health. The case studies provide valuable insights into the specific scenarios and challenges faced in different regions of the world, aiding in a better understanding of mucormycosis and its management.